U.S. Communications Stock News

When you buy and hold a stock for the long term, you definitely want it to provide a positive return. Better yet, you'd...

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...

When you buy and hold a stock for the long term, you definitely want it to provide a positive return. Better yet, you'd...

Those holding AeroVironment, Inc. ( NASDAQ:AVAV ) shares would be relieved that the share price has rebounded 49% in...

ITT's (NYSE:ITT) stock is up by 6.5% over the past three months. Since the market usually pay for a company’s long-term...

If you are looking at Xeris Biopharma Holdings and wondering whether the recent excitement still offers fair value, this article will walk you through what the current price might be implying. The stock last closed at US$7.93, with returns of 7.9% over the past week, 14.3% over the past month, 7.9% year to date, and 133.2% over the last year, along with a very large 3 year return that is more than 5x. Recent company news has put a spotlight on Xeris Biopharma Holdings, adding context to...

With a median price-to-sales (or "P/S") ratio of close to 0.5x in the Specialty Retail industry in the United States...

Steel Partners Holdings (SPLP) is on investors’ radar after recent share price moves, with the stock showing double digit returns over the month and the past 3 months, prompting fresh interest in its diversified operations. See our latest analysis for Steel Partners Holdings. That recent momentum sits on top of a solid year, with a 13.83% year to date share price return and a 1 year total shareholder return of 17.94%. The 5 year total shareholder return is a little under 3x. If SPLP’s move...

We wouldn't blame Gulfport Energy Corporation ( NYSE:GPOR ) shareholders if they were a little worried about the fact...

LENZ Therapeutics (LENZ) shares are in focus after the company signed an exclusive distribution agreement with Lunatus Marketing & Consulting FZCO to register and commercialize its VIZZ eye drop for presbyopia across multiple Middle Eastern markets. See our latest analysis for LENZ Therapeutics. The distribution deal comes after a weak run for the stock, with a 30 day share price return of 40.62% and a 90 day share price return of 61.67%, while the 1 year total shareholder return sits at...

Interface (NASDAQ:TILE) has had a great run on the share market with its stock up by a significant 15% over the last...

CVD Equipment Corporation ( NASDAQ:CVV ) shareholders have had their patience rewarded with a 36% share price jump in...

Angi Inc.'s ( NASDAQ:ANGI ) price-to-earnings (or "P/E") ratio of 17.2x might make it look like a buy right now...

Despite an already strong run, Astronics Corporation ( NASDAQ:ATRO ) shares have been powering on, with a gain of 28...

Let's talk about the popular Charles River Laboratories International, Inc. ( NYSE:CRL ). The company's shares saw a...

While Townsquare Media, Inc. ( NYSE:TSQ ) might not have the largest market cap around , it received a lot of attention...

Diversification is a key tool for dealing with stock price volatility. But the goal is to pick stocks that do better...

Lam Research Corporation ( NASDAQ:LRCX ) shares have continued their recent momentum with a 30% gain in the last month...

Insiders were net sellers of Optimum Communications, Inc.'s ( NYSE:OPTU ) stock during the past year. That is, insiders...

Alamo Group Inc.'s ( NYSE:ALG ) dividend will be increasing from last year's payment of the same period to $0.34 on...

If you are wondering whether N-able's share price around US$7.31 actually reflects its underlying worth, you are not alone. This article is built to help you size that up clearly. Over the past week the stock is roughly flat at a 0.1% return, but that sits against a 4.2% decline over 30 days and a 19.7% decline over the past year, which can change how investors view both its potential and its risks. Recent coverage has focused on how N-able is positioned within the broader software and IT...

If you have been wondering whether P10 is priced attractively right now, you are not alone. Many investors are asking the same question about what they are really paying for with this stock. P10 shares last closed at US$10.33, with recent returns of 4.4% over the past week, 1.2% over the past month, 4.4% year to date, and a 17.6% decline over the past year and 7.6% decline over three years. Recent market attention on P10 has been shaped by ongoing discussion around its role in the...

Immuneering Corporation recently reported updated Phase 2a data showing encouraging overall survival, response, and safety outcomes for its atebimetinib plus modified gemcitabine/nab-paclitaxel regimen in previously untreated pancreatic cancer patients, and confirmed plans to begin a pivotal Phase 3 trial in mid-2026. A key nuance is that the reported survival benefit is based on comparisons to historical MPACT trial benchmarks rather than a head-to-head control arm, which may influence how...

Soho House & Co (SHCO) has recently drawn investor attention after a period of mixed share performance, with the stock showing a small positive 1 year total return alongside negative moves over the past week, month and past 3 months. See our latest analysis for Soho House & Co. The recent 1 day share price return of 2.59% decline, alongside weaker 7 day and 30 day share price returns, suggests fading short term momentum, even as the 3 year total shareholder return of 48.78% points to a...